Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The state-of-the-art facility provides a pathway from development to large-scale biologics production
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated
